A liver disease that kills faster than most cancers has few options beyond a transplant. A new partnership aims to change where care happens. #longevity# #liverdisease# #liverhealth# #transplant# #healthcare#

#HepatitisB# and #HepatitisC# can lead to serious liver disease and are major causes of #LiverCancer#. The good news? Testing can help catch these infections early—even if you feel healthy. Talk to your health care provider about getting tested. Prevention starts with knowing your status: #LCAM# #LiverCancer# #LiverCancerAwareness#

GLP-1 Shows Promise for Patients with Advanced Fatty Liver Disease Clinical trial of semaglutide drug is first to show improvement in liver scarring among patients with early cirrhosis 🔬Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial

Move Over, Lycopene. Tomatoes’ Secret Sauce May Be Phytoene New study suggests a lesser-known compound in tomatoes may help protect against fatty liver disease, which affects more than 1 in 3 American adults

I'm a cardiologist. Curcumin may be one of the most legitimately promising anti-inflammatory compounds available — and the exact form that works best is the one with documented cases of liver injury. That tension is the whole story, and almost nobody tells it honestly. Let me give you both halves. First, why the form matters more than the compound. Standard turmeric and cheap curcumin are almost pharmacologically useless. Absorption is dismal, the liver metabolizes it within minutes, and blood levels barely register. Most people taking turmeric capsules are essentially taking an expensive yellow placebo. Phytosomal curcumin — curcumin bound to phospholipids, the best-studied being Meriva — changes that completely. A randomized crossover trial in the Journal of Natural Products found 29-fold higher total absorption compared to standard curcuminoids. That single fact explains why decades of curcumin research looked underwhelming. We were testing a molecule that never reached the bloodstream. What the absorbed form actually does. It works upstream, at the genetic level, by downregulating NF-κB — the master switch controlling inflammatory gene expression. Downstream of that: reduced TNF-alpha, IL-6, and COX-2. TNF-alpha is the one I find most interesting. It's a central driver of "inflammaging" — the chronic low-grade inflammation that accelerates biological aging. It's the same target as the TNF-inhibitor drugs used in rheumatoid arthritis, which observational data has linked to substantially lower Alzheimer's risk. Lowering TNF-alpha through a supplement is not the same as a biologic drug. But the pathway is real, and it's the right pathway. The human evidence that impressed me most. This isn't cell culture. In a multicenter randomized trial, 52 biopsy-proven MASH patients received Meriva 2g/day or placebo for 72 weeks. Biopsy-proven. Seventy-two weeks. That's a serious trial design for a supplement. Additional randomized trials in NAFLD have shown reductions in ALT, AST, cholesterol, triglycerides, waist circumference, and liver volume. As a cardiologist, that matters — fatty liver and cardiovascular disease share the same metabolic root, and ALT is one of the most underread markers on a standard panel. Now the part the enthusiasts leave out. The NIH's LiverTox database documents several dozen cases of clinically apparent acute liver injury attributed to turmeric products — and it specifically implicates the high-bioavailability forms. There was an outbreak of acute hepatitis with jaundice in Italy traced to enhanced-absorption curcumin. Sit with the irony: the reason these formulations work is the same reason they can hurt you. You made a poorly absorbed compound highly absorbed. You did not merely increase the benefit. You increased the dose the liver actually sees. A genetic susceptibility has been identified — an HLA variant that appears to predispose certain people. Most will never have a problem. Some will. And a note on piperine. Many products add black pepper extract to boost absorption. It works — by inhibiting the liver enzymes that clear the compound. That same mechanism affects how your liver clears your other medications. If you take anything metabolized hepatically, this matters. Meriva achieves its absorption through phospholipids rather than enzyme blockade, which is one argument in its favor. So where do I land? This is one of the few natural compounds with genuine randomized human data hitting a mechanism that matters. I take it seriously. But treat it like a drug, because pharmacologically that is what an enhanced-absorption formulation is. Get a baseline ALT and AST before starting, and recheck at 8-12 weeks. That single step converts an unmonitored risk into a managed one, and virtually nobody does it. Skip it entirely if you have existing liver disease, gallbladder disease, or bile duct obstruction. Curcumin stimulates gallbladder contraction and can worsen biliary colic. Be cautious if you're on blood thinners — it has antiplatelet effects. And stop immediately for dark urine, yellowing eyes, right upper quadrant pain, or unexplained fatigue. The lesson underneath this is bigger than curcumin. We've been trained to believe "natural" means "safe," so we skip the monitoring we'd never skip with a prescription. But a supplement engineered for 29-fold absorption isn't a spice anymore. It's pharmacology in a capsule with no oversight. The compound may genuinely help you. Just check your liver while it does.

Dr Jeremy Nayagam speaks live from EASL 2026, highlighting research on genetic testing in adults with unexplained cholestatic liver disease and hepatitis. Watch the full video now, and explore our coverage of the congress.

Last month Moderna reported the first individualized cancer vaccine to pass a Phase 3. Moderna CEO Stéphane Bancel and a16z's Jorge Conde on what that actually means: The treatment works by sequencing a patient’s tumor and healthy cells, identifying the mutations relevant to their cancer, and encoding up to 34 of them into an mRNA specific to the individual. Rather than simply unleashing the immune system, the goal is to teach it what to recognize and attack. In this conversation, they unpack the engineering challenge of manufacturing a different medicine for every patient, how Moderna has brought the process down to roughly 42 days from biopsy to treatment, and what it would take to manufacture personalized medicines at scale. 00:00 Intro 02:35 A Phase 3 that beat the standard of care 06:00 Why today's immunotherapy fails 40% of patients 09:35 A vaccine for cancer you already have 11:20 Why mRNA worked where 1,000 trials failed 13:15 90% of cancer antigens are unique to you 16:35 Why this vaccine only gets better from here 21:00 The only thing Moderna needs is your DNA sequence 22:20 Why the first robot was intentionally inefficient 27:10 How the FDA approves a drug that's different every time 33:05 A cancer treatment with the side effects of a flu shot 33:30 Why pancreatic cancer is worth a risk 36:30 Rare liver disease next, then autoimmune YouTube: @moderna_tx @JorgeCondeBio

I want to tell you why I brought this test into my practice. After more than two decades in cardiology, I've learned that the most painful sentence in medicine isn't "you have cancer." It's "we caught it too late." I've watched patients survive their heart disease — do everything right, transform their numbers, add years to their life — and then be taken by a pancreatic or ovarian cancer that nobody was looking for, because no screening test for it existed. Those losses stayed with me. They're the reason I've spent months studying the science behind multi-cancer early detection, and the reason the Galleri test is now available in my office. Here's what it is: a single blood draw that screens for a signal from more than 50 cancers — most of which have no routine screening in this country. It works by reading the molecular fingerprint that tumors shed into your bloodstream, and when it detects something, it also tells us which organ the signal most likely came from, so we know exactly where to look. I chose this particular test after reviewing the whole field, and I chose it for one reason above all: it is the only multi-cancer test that has been studied prospectively in more than 142,000 people who felt completely healthy — the hardest and most honest way to test a screening tool. Who should consider it: adults 50 and older, and anyone at elevated risk at a younger age — a strong family history of cancer, a known genetic predisposition, a significant smoking history, chronic liver disease, obesity or long-standing metabolic disease, or a prior cancer diagnosis. It is not a replacement for your mammogram, colonoscopy, or other standard screenings — please keep every one of those. It's an additional layer, aimed at the cancers we currently don't look for at all. And here is the whole point, in one sentence: for most cancers, early is curable and late is not. Survival for many of the deadliest cancers falls from 80 or 90 percent when caught early to single digits once they've spread. Same disease, same treatments — the only thing that changed is when we found it. That window is everything, and this test is a chance to find it while the window is still open. Please read the full article I've written below. I've laid out exactly how the technology works, what the trials actually showed — including their limitations, because you deserve the honest version — and how to think clearly about whether this is right for you. Then, if you'd like to discuss it, ask us at your next visit or call the office. I'd rather have this conversation with you now than have a different one later.